Fast-paced Momentum Stock Avinger (AVGR) Is Still Trading at a Bargain
- Avinger (AVGR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
- 04/15/2024
|
Avinger (AVGR) Upgraded to Buy: What Does It Mean for the Stock?
- Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 03/25/2024
|
Avinger, Inc. (AVGR) Q4 2023 Earnings Call Transcript
- Avinger, Inc. (AVGR) Q4 2023 Earnings Call Transcript
- 03/20/2024
|
Avinger Reports Fourth Quarter and Full Year 2023 Results
- New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens New Pathway for Sales in Asia REDWOOD CITY, CA / ACCESSWIRE / March 20, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Recent Highlights Announced up to $15 million strategic financing and partnership agreement with Zylox-Tonbridge, a leading provider of neuro- and peripheral-vascular interventional solutions in China, with $7.5 million initial equity investment funded in March 2024 Reported fourth quarter 2023 revenue of $1.9 million, a sequential increase of 5%, and gross margin of 20% Expanded sales team by more than 25% and deepened Avinger's presence in key Midwest, Texas and Florida markets Expanded full commercial launch of Tigereye ST, Avinger's most advanced image-guided peripheral CTO-crossing device, based on strong momentum in the fourth quarter Continued limited launch of the new Pantheris LV (large vessel) image-guided atherectomy device in anticipation of full commercial launch Advanced development of proprietary image-guided coronary CTO-crossing system, including completion of Phase 2 design selection and multiple rounds of animal and cadaver heart studies, with IDE submission anticipated in the third quarter of 2024 "We are excited to begin our strategic partnership with Zylox-Tonbridge, a dynamic leader in the peripheral interventional market in China," said Jeff Soinski, Avinger's President and CEO.
- 03/20/2024
|
Avinger to Announce Full Year 2023 Results on March 20, 2024
- REDWOOD CITY, CA / ACCESSWIRE / March 12, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the fourth quarter and full year 2023 after the close of trading on Wednesday, March 20, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
- 03/12/2024
|
Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions
- HANGZHOU, China, March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market in China, today announced a new strategic partnership with Avinger, a commercial-stage medical device company developing and marketing the first and only intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease. This partnership includes an exclusive right to Zylox-Tonbridge to localize, manufacture, and commercialize the entire product family developed by Avinger in Greater China (including Mainland China, Hong Kong, Taiwan, and Macau), and a technology transfer agreement to leverage Zylox-Tonbridge cost-efficient manufacturing capacity to support Avinger's global sales outside of Greater China.
- 03/07/2024
|
Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge
- Initial $7.5 Million Strategic Investment Strategic Partnership Opens Pathway to Access Greater China Market Strengthened Balance Sheet and Three-Year Extension of Existing Debt Terms REDWOOD CITY, CA / ACCESSWIRE / March 6, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced a new strategic partnership with Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, "Zylox-Tonbridge"), a leading medical device company in the neuro- and peripheral-vascular interventional market in China.
- 03/06/2024
|
Avinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates
- Avinger (AVGR) came out with a quarterly loss of $2.92 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to loss of $11.54 per share a year ago.
- 10/26/2023
|
Avinger, Inc. (AVGR) Q3 2023 Earnings Call Transcript
- Avinger, Inc. (NASDAQ:AVGR ) Q3 2023 Earnings Conference Call October 26, 2023 4:30 PM ET Company Participants Matt Kreps - Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Operator Greetings. Welcome to the Avinger Third Quarter 2023 Results Conference Call.
- 10/26/2023
|
Avinger Reports Third Quarter 2023 Results
- REDWOOD CITY, CA / ACCESSWIRE / October 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2023. Third Quarter and Recent Highlights Third quarter revenue of $1.8 million, and gross margin of 21% Initiated full commercial launch for Tigereye ST, Avinger's most advanced image-guided CTO-crossing device, in September Commenced limited launch of the new Pantheris LV (large vessel) image-guided atherectomy device Advanced development of the first-ever image-guided coronary CTO-crossing system, including successful completion of additional animal and cadaver heart studies, in preparation for IDE submission anticipated mid-2024 Named Phil Preuss to new position of Chief Commercial Officer in October, to lead sales force expansion and drive revenue growth initiatives Released updated, best-in-class interim data from the Pantheris SV IMAGE-BTK (below-the-knee) study in key opinion leader presentation at the AMP clinical conference Strengthened balance sheet through conversion of $1.9 million or 12% of outstanding debt to a new series of convertible preferred stock, and raising net proceeds of $5.1 million through the sale of common stock in the company's at-the-market (ATM) facility "With full commercial launch of our Tigereye ST CTO-crossing catheter and limited launch of our new Pantheris LV image-guided atherectomy system in the third quarter, exciting new clinical outcomes data for our Pantheris SV below-the-knee atherectomy device, and the outstanding performance and increased mobility of our Lightbox 3 imaging console launched last year, we have built the most advanced peripheral products portfolio in the industry," commented Jeff Soinski, Avinger's President and CEO.
- 10/26/2023
|
Avinger to Announce Third Quarter 2023 Results on October 26
- REDWOOD CITY, CA / ACCESSWIRE / October 19, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2023 after the close of trading on Thursday, October 26, 2023. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
- 10/19/2023
|
Avinger Raises $5.3 Million via At-The-Market Facility
- Strengthens Balance Sheet in Support of Tigereye ST Launch and Coronary Product Development REDWOOD CITY, CA / ACCESSWIRE / September 27, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that is has raised gross proceeds of approximately $5.3 million through its at-the-market (ATM) facility in September 2023, selling an aggregate of 596,200 shares of common stock at a weighted average price of $8.97. Net proceeds from the transactions were approximately $5.2 million after deducting sales commissions.
- 09/27/2023
|
Avinger stock rockets off a record low after launch of vascular disease treatment system
- Shares of Avinger Inc. skyrocketed 63.5% on heavy volume in morning trading Monday, enough to make them the biggest gainers trading on major U.S. exchanges, after the medical device company announced the commercial launch of its Tigereye ST, an image-guided catheter-based system for the diagnosis and treatment of vascular disease. Trading volume soared to 26.5 million shares, compared with the full-day average of about 9,300 shares.
- 09/18/2023
|
Avinger Initiates Full Commercial Launch of Tigereye ST Image-Guided CTO Crossing Device
- REDWOOD CITY, CA / ACCESSWIRE / September 18, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial launch of its Tigereye® ST next generation image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, all current and prospective accounts can now order the Tigereye ST device.
- 09/18/2023
|
Avinger Announces Presentations by Key Opinion Leaders at AMP (The Amputation Prevention Symposium) 2023
- REDWOOD CITY, CA / ACCESSWIRE / August 24, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced three podium presentations featuring the company's Lumivascular technology at The Amputation Prevention Symposium, held from August 16 through August 19 in Chicago, Illinois. AMP focuses on education and technologies for treating critical limb ischemia, an advanced stage of PAD, in patients facing a life-altering amputation.
- 08/24/2023
|
Avinger Announces Conversion of 12% of CRG Term Debt into Equity
- REDWOOD CITY, CA / ACCESSWIRE / August 4, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the conversion of approximately 12% of its existing debt with entities affiliated with CRG Partners III L.P. ("CRG") into shares of a new series of convertible preferred stock.
- 08/04/2023
|
Avinger, Inc. (AVGR) Q2 2023 Earnings Call Transcript
- Avinger, Inc. (NASDAQ:AVGR ) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Greetings and welcome to the Avinger Second Quarter 2023 Results Call.
- 07/27/2023
|
Avinger (AVGR) Reports Q2 Loss, Misses Revenue Estimates
- Avinger (AVGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.94 per share a year ago.
- 07/27/2023
|
Avinger, Inc. (AVGR) Q1 2023 Earnings Call Transcript
- Avinger, Inc. (NASDAQ:AVGR ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Kreps – Darrow Associates Investor Relations Jeff Soinski – Chief Executive Officer Nabeel Subainati – Principal Financial Officer Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Greetings, and welcome to the Avinger First Quarter 2023 Results Call.
- 05/10/2023
|
Avinger to Announce First Quarter 2023 Results on May 10
- REDWOOD CITY, CA / ACCESSWIRE / May 2, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the first quarter 2023 after the close of trading on Wednesday, May 10, 2023. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
- 05/02/2023
|
Top Penny Stocks To Buy? 4 Under $1 To Watch This Week
- Penny stocks to buy for under $1 but are they worth the risk this week? The post Top Penny Stocks To Buy?
- 04/26/2023
|
Avinger, Inc (AVGR) Q4 2022 Earnings Call Transcript
- Avinger, Inc (NASDAQ:AVGR ) Q4 2022 Earnings Call March 15, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates Investor Relations Jeff Soinski - President, CEO & Director Nabeel Subainati - VP, Controller, Principal Financial Officer & Accounting Officer Conference Call Participants Ramakanth Swayampakula - HC Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Avinger Fourth Quarter and Full Year 2022 Results Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation.
- 03/15/2023
|
Avinger to Announce Fourth Quarter 2022 Results on March 15
- REDWOOD CITY, CA / ACCESSWIRE / March 2, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the fourth quarter and full year 2022 after the close of trading on Wednesday, March 15, 2023. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
- 03/02/2023
|
Avinger, Inc (AVGR) Q3 2022 Earnings Call Transcript
- Start Time: 16:30 January 1, 0000 4:50 PM ET Avinger, Inc (NASDAQ:AVGR ) Q3 2022 Earnings Conference Call November 09, 2022, 16:30 PM ET Company Participants Jeff Soinski - CEO Nabeel Subainati - Principal Financial Officer Matt Kreps - IR Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Avinger Third Quarter 2022 Results Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation.
- 11/13/2022
|
Avinger to Announce Third Quarter 2022 Results on November 9
- REDWOOD CITY, CA / ACCESSWIRE / November 1, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2022 after the close of trading on Wednesday, November 9, 2022. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
- 11/01/2022
|
Avinger to Present at LD Micro Investor Conference
- REDWOOD CITY, CA / ACCESSWIRE / October 19, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced that Chief Executive Officer Jeff Soinski will participate in the following investor conference event during October 2022. Event: LD Micro Main Event XV Date: Tuesday, October 25, 2022 Presentation: 10:00 a.m.
- 10/19/2022
|
Avinger, Inc.'s (AVGR) CEO Jeff Soinski on Q2 2022 Results - Earnings Call Transcript
- Avinger, Inc. (NASDAQ:AVGR ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Kreps – Investor Relations Jeff Soinski – Chief Executive Officer Nabeel Subainati – Principal Financial Officer Conference Call Participants Operator Good day, everyone, and welcome to today's Avinger Second Quarter 2020 Results Call. [Operator Instructions] Please note, this call may be recorded.
- 08/12/2022
|
Avinger to Announce Second Quarter 2022 Results on August 11
- REDWOOD CITY, CA / ACCESSWIRE / August 5, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2022 after the close of trading on Thursday, August 11, 2022. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
- 08/05/2022
|
Avinger, Inc. (AVGR) CEO Jeffery M. Soinski on Q1 2022 - Earnings Call Transcript
- Avinger, Inc. (NASDAQ:AVGR ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jeffery M. Soinski – Chief Executive Officer Mark Weinswig – Chief Financial Officer Matthew Kreps – Darrow Associates Investor Relations Conference Call Participants Marc Weisenberger – B.
- 05/10/2022
|
Avinger (AVGR) Reports Q1 Loss, Misses Revenue Estimates
- Avinger (AVGR) delivered earnings and revenue surprises of -92.56% and 0.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2022
|
Avinger to Announce First Quarter 2022 Results on May 10
- REDWOOD CITY, CA / ACCESSWIRE / April 29, 2022 / Avinger, Inc. (Nasdaq:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2022 after the close of trading on Tuesday, May 10, 2022. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
- 04/29/2022
|
Avinger (AVGR) Reports Q4 Loss, Tops Revenue Estimates
- Avinger (AVGR) delivered earnings and revenue surprises of 0% and 4.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/22/2022
|
Avinger, Inc.'s (AVGR) CEO Jeff Soinski on Q4 2021 Results - Earnings Call Transcript
- Avinger, Inc.'s (AVGR) CEO Jeff Soinski on Q4 2021 Results - Earnings Call Transcript
- 03/22/2022
|
Avinger Registers 12% Decline In Q4 Revenue, Says Hospital Constraints Impacted Q4
- Avinger Inc (NASDAQ: AVGR) reported a fourth-quarter revenue decrease of 12% year-over-year to $2.40 million, beating the consensus of $2.29 million. Hospital constraints impacted Q4 on procedural volume and hospital staffing shortages related to the resurgence of COVID-1.
- 03/22/2022
|
Top Penny Stocks To Buy Right Now? 4 Short Squeeze Stocks To Watch
- Short squeeze penny stocks to watch right now. The post Top Penny Stocks To Buy Right Now?
- 03/18/2022
|
Avinger to Announce Full-Year 2021 Results on March 22
- REDWOOD CITY, CA / ACCESSWIRE / March 15, 2022 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2021 after the close of trading on Tuesday, March 22, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
- 03/15/2022
|
Avinger (AVGR) Stock: Why It Jumped Up Today
- The Avinger Inc (NASDAQ: AVGR) stock increased by over 20% during intraday trading today. This is why.
- 03/01/2022
|
Avinger Stock Surges As Pantheris Scores FDA Approval For In-Stent Restenosis Indication
- Avinger Inc (NASDAQ:AVGR) received 510(k) clearance from the FDA for a new clinical indication for the Pantheris image-guided atherectomy system. The clearance allows the Company to directly market Pantheris for in-stent restenosis (ISR) in the lower extremity arteries.
- 11/17/2021
|
Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?
- Today's hot penny stocks are catching the eyes of investors and we're diving into everything investors need to know about them on Wednesday! The post Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?
- 11/17/2021
|
Avinger, Inc.'s (AVGR) CEO Jeff Soinski on Q3 2021 Earnings Conference Call - Earnings Call Transcript
- Avinger, Inc.'s (AVGR) CEO Jeff Soinski on Q3 2021 Earnings Conference Call - Earnings Call Transcript
- 11/11/2021
|
Avinger (AVGR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Avinger (AVGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/04/2021
|
Avinger to Announce Third Quarter Results on November 11, 2021
- REDWOOD CITY, CA / ACCESSWIRE / October 29, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the third quarter 2021 after the close of trading on Thursday, November 11, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
- 10/29/2021
|
Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA
- Study Outcomes Demonstrate Safety and Efficacy of Pantheris for Treatment of In-Stent Restenosis REDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that clinical data from the INSIGHT study were presented during the Late-Breaking Clinical Trials session at the VIVA (Vascular InterVentional Advances) conference in Las Vegas. The INSIGHT trial was designed to evaluate the safety and effectiveness of Avinger's Pantheris image-guided atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries.
- 10/07/2021
|
Avinger To Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
- REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its management will participate in investor meetings September 13-15, 2021 as part of the H.C. Wainwright 23rd Annual Global Investment Conference.
- 09/08/2021
|
Avinger OCT-Guided Technologies Featured at AMP 2021
- REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced presentations featuring the Company's Lumivascular, OCT-guided, technologies at the annual AMP (Amputation Prevention Symposium) conference occurring last week. AMP focuses on education and technologies for treating critical limb ischemia (CLI), an advanced stage of PAD, in patients facing a life-altering amputation.
- 08/16/2021
|
Avinger, Inc. (AVGR) CEO Jeff Soinski on Q2 2021 Results - Earnings Call Transcript
- Avinger, Inc. (AVGR) CEO Jeff Soinski on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
Avinger: Q2 Earnings Insights
- Shares of Avinger (NASDAQ:AVGR) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 77.78% year over year to ($0.04), which were in line with the estimate of ($0.04).
- 08/10/2021
|
Avinger Reports Second Quarter 2021 Financial Results
- Pantheris Sales and Tigereye™ Expansion Drive 91% Year-Over-Year Revenue Growth REDWOOD CITY, CA / ACCESSWIRE / August 10, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights Revenue increased 91% year-over-year to $2.8 million, fueled by Pantheris sales growth and new Tigereye CTO sales Record Pantheris SV revenue reflects strong market adoption of Avinger's small-vessel catheter, primarily used in below-the-knee (BTK) applications Image-guided CTO revenue increased 114% year-over-year, driven by Tigereye launch at more than 40 sites Gross margin increased to 36% as Avinger scales its operations Opened more than 30 new Lumivascular accounts in the last 12 months on increased market demand for Avinger's highly differentiated technology Filed 510(k) in June to expand Pantheris clinical indication for treatment of in-stent restenosis (ISR) Filed 510(k) in August for the Lightbox 3 next generation imaging console Maintained strong cash position of $26.7 million at June 30, 2021, anticipated to fund sales force expansion, new product development and clinical plans through 2022 Jeff Soinski, Avinger's President and CEO, commented, "Avinger's 2021 growth momentum continued in the second quarter as we delivered strong revenue gains for both our Pantheris atherectomy and image-guided CTO product lines and procedural volume improving in the first half of the year.
- 08/10/2021
|
Avinger Announces 510(k) Filing for New Lightbox 3 Imaging Console
- Smaller Footprint, Improved User Experience and Lower Cost to Drive Adoption REDWOOD CITY, CA / ACCESSWIRE / August 9, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console. "Avinger's Lightbox 3 represents an important leap forward in imaging, portability and capability," commented Jeff Soinski, Avinger's President and CEO.
- 08/09/2021
|
Avinger Announces 510(k) Filing for New Pantheris In-Stent Restenosis Indication
- REDWOOD CITY, CA / ACCESSWIRE / July 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for a new Pantheris clinical indication for the treatment of in-stent restenosis (ISR) in the lower extremity arteries. Highlighting the importance of this submission, Jeff Soinski, Avinger's President and CEO commented, "We are extremely pleased with this milestone and the initial clinical data generated from the INSIGHT trial that supports the 510(k) submission.
- 07/06/2021
|
5 Red-Hot Stocks Under $10 With Big Upside Potential
- While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- 07/03/2021
|
Hot Penny Stocks to Buy to Avoid Inflation? 7 For Your July Watchlist
- Which penny stocks are investors watching with inflation on the rise? Here's 7 for your list The post Hot Penny Stocks to Buy to Avoid Inflation?
- 06/30/2021
|
AVGR Stock Price Increases Over 16%: Why It Happened
- The stock price of Avinger Inc (NASDAQ: AVGR) increased by over 16% during intraday trading. This is why it happened.
- 06/29/2021
|
Avinger Announces Key Opinion Leader Presentations at Vascular Conferences in Germany
- REDWOOD CITY, CA / ACCESSWIRE / June 28, 2021 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced key opinion leader (KOL) presentations featuring the company's Lumivascular technology at two important vascular conferences held in Germany: the annual German CLI Congress and the Essen Vascular Conference. Dr. Arne Schwindt, a vascular surgeon from St. Franziskus Hospital Münster in Germany, gave a presentation featuring Avinger's Lumivascular technology at the annual Critical Limb Ischemia (CLI) Congress in Germany.
- 06/28/2021
|
Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
- REDWOOD CITY, CA / ACCESSWIRE / June 7, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced two podium presentations featuring the company's Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which took place June 1 through June 4 in New Orleans. Key opinion leaders in the fields of interventional cardiology and endovascular interventions highlighted Avinger's Lumivascular technology in the following sessions: Dr. Jon George, an interventional cardiologist and endovascular medicine specialist at Pennsylvania Hospital, University of Pennsylvania Health System in Philadelphia, included Avinger's proprietary OCT-guided platform in his session, "Are Intravascular Ultrasound and OCT Being Utilized Enough in Peripheral Interventions?
- 06/07/2021
|
Avinger Announces Issuance and Allowance of Seven U.S. Patents
- REDWOOD CITY, CA / ACCESSWIRE / May 25, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the issuance and allowance of seven U.S. patents to date in 2021. These new U.S. patents include a wide range of claims relating to Avinger's proprietary optical coherence tomography (OCT) intravascular imaging system and its OCT-guided catheters for the treatment of vascular disease.
- 05/25/2021
|
Avinger, Inc. (AVGR) CEO Jeff Soinski on Q1 2021 Results - Earnings Call Transcript
- Avinger, Inc. (AVGR) CEO Jeff Soinski on Q1 2021 Results - Earnings Call Transcript
- 05/06/2021
|
3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383%
- Penny stocks to buy according to top Wall Street analysts The post 3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/30/2021
|
Avinger to Announce First Quarter 2021 Results on May 6, 2021
- REDWOOD CITY, CA / ACCESSWIRE / April 26, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2021 after the close of trading on Thursday, May 6, 2021. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
- 04/26/2021
|
Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus
- List Of Penny Stocks To Watch Right Now The post Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/21/2021
|
New Publications Highlight Clinical Benefits of Avinger PAD Therapies
- REDWOOD CITY, CA / ACCESSWIRE / April 21, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the publication of two clinical studies in peer-reviewed journals, further supporting the clinical benefits of its therapeutic devices. The studies were based on separate clinical case series conducted by physicians at the Division of Cardiovascular Disease and Endovascular Medicine at the Einstein Medical Center in Philadelphia, Pennsylvania.
- 04/21/2021
|
Avinger Provides Update on Tigereye(TM) Commercial Launch
- REDWOOD CITY, CA / ACCESSWIRE / April 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the commercial launch of Tigereye CTO Crossing catheters for the treatment of PAD. Following limited launch in the fourth quarter of 2020, Avinger initiated full commercial launch of Tigereye in January 2021.
- 04/08/2021
|
Target Top-Line Growth and Compelling Patient Outcomes with Avinger
- It's been reported that AVGR stock is popular among Robinhood traders. That's fine, but it's more important to see the company's potential.
- 03/30/2021
|
Avinger, Inc. (AVGR) CEO Jeff Soinski on Q4 2020 Results - Earnings Call Transcript
- Avinger, Inc. (AVGR) CEO Jeff Soinski on Q4 2020 Results - Earnings Call Transcript
- 03/11/2021
|
Avinger: Q4 Earnings Insights
- Avinger (NASDAQ:AVGR) reported Q4 results on Thursday afternoon. Quarterly Results Earnings per share were up 87.93% over the past year to ($0.07), which missed the estimate of ($0.06).
- 03/11/2021
|
Avinger Reports Fourth Quarter 2020 Financial Results
- 19% Sequential Increase in Total Revenue Tigereye™ Drives 38% Sequential Growth in Image-Guided CTO Revenue REDWOOD CITY, CA / ACCESSWIRE / March 11, 2021 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the fourth quarter ended December 31, 2020. Fourth Quarter and Recent Highlights Revenue increased 19% sequentially to $2.7 million, the highest level in 3 years Image-guided CTO revenue increased 38% sequentially, driven by limited launch of the new Tigereye™ device Gross margin rose sequentially to 36%, reflecting increased sales activity and cost efficiency Opened 9 new Lumivascular accounts in the fourth quarter, bringing total new accounts for the full year to 36 Progressed Tigereye to full commercial launch in January 2021, following successful limited launch in the fourth quarter Improved the terms of Avinger's existing loan agreement in January 2021, including the extension of the maturity date to 2025 Ended December 31, 2020 with cash on hand of $22.2 million and added approximately $13 million in net proceeds from a common stock offering in February 2021 Jeff Soinski, Avinger's President and CEO, commented, "Avinger remains focused on driving top-line growth by introducing new products, launching new accounts and expanding utilization at existing sites.
- 03/11/2021
|
Avinger, Inc. to Present at the Q1 Virtual Investor Summit
- REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire- Avinger, Inc. (Nasdaq: AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that Mark Weinswig, CFO, will be attending the Q1 Virtual Investor Summit. Management will conduct an overview presentation available on the investor relations section of Avinger's website, www.avinger.com , and be available for one-on-one investor meetings throughout the day.
- 03/11/2021
|
Earnings Outlook For Avinger
- Avinger (NASDAQ:AVGR) announces its next round of earnings this Thursday, March 11. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement.
- 03/10/2021
|
Avinger to Announce Fourth Quarter Full Year 2020 Results on March 11, 2021
- REDWOOD CITY, CA / ACCESSWIRE / March 2, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2020 after the close of trading on Thursday, March 11, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
- 03/02/2021
|
AVGR Stock: The Social Media Buzz That Has Avinger Shares Soaring
- Avinger (AVGR) stock is on the rise Thursday despite there being no new news from the company but chatter about a patent on social media. The post AVGR Stock: The Social Media Buzz That Has Avinger Shares Soaring appeared first on InvestorPlace.
- 02/18/2021
|
AVGR Stock Price Increases Over 60% Pre-Market: Why It Happened
- The stock price of Avinger Inc (NASDAQ: AVGR) is trading at over 60% pre-market as of 6:09 AM ET. This is why it happened.
- 02/18/2021
|
Avinger Expands Intellectual Property Portfolio
- 19 New U.S. and International Patents Issued and Allowed in 2020 REDWOOD CITY, CA / ACCESSWIRE / January 19, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the expansion of its intellectual property portfolio in 2020. Avinger announced the issuance and allowance of 10 new patents in the U.S. and 9 new patents in international markets in 2020, including 7 new patents related to its recently introduced Tigereye™ image-guided CTO crossing catheter.
- 01/19/2021
|
AVGR Stock Price Increased 32.43%: Why It Happened
- The stock price of Avinger Inc (NASDAQ: AVGR) increased by 32.43% on January 15. This is why it happened.
- 01/16/2021
|
AVGR Stock: 11 Things to Know About Avinger as Shares Rocket Higher
- Avinger (AVGR) stock is taking off on Friday after announcing the full commercial release of its Tigereye medical device. The post AVGR Stock: 11 Things to Know About Avinger as Shares Rocket Higher appeared first on InvestorPlace.
- 01/15/2021
|
Avinger Initiates Full Commercial Launch of Tigereye(TM) Image-Guided CTO Crossing Catheter
- REDWOOD CITY, CA / ACCESSWIRE / January 15, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced full commercial launch of its Tigereye™ image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, current and prospective accounts throughout the US and Germany are now able to order the Tigereye device.
- 01/15/2021
|
AVGR Stock: 6 Things to Know About ‘Robinhood's Hot Penny Stock to Buy' Avinger
- Avinger (AVGR) is seeing a massive boost to its stock on Friday after being listed as a hot penny stock to buy on Robinhood. The post AVGR Stock: 6 Things to Know About ‘Robinhood's Hot Penny Stock to Buy' Avinger appeared first on InvestorPlace.
- 01/08/2021
|
Avinger to Participate in HC Wainwright Conference
- REDWOOD CITY, CA / ACCESSWIRE / January 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its executive team will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021.
- 01/06/2021
|
AVGR Stock Price Increased 65.48% This Month: Why It Happened
- The stock price of Avinger Inc (NASDAQ: AVGR) increased by 65.48% this past month. This is why it happened.
- 12/25/2020
|
Avinger Announces Annual Meeting Results
- REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020. At the Annual Meeting, proposals were presented to elect one director to serve until the 2023 annual meeting, to ratify the appointment of the Company's public accountant for the year ended December 31, 2020, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split, and to adjourn the Annual Meeting for the purpose of continuing to solicit votes with respect to the proposals presented.
- 12/23/2020
|
Avinger's (AVGR) CEO Jeff Soinski on Q3 2020 Results - Earnings Call Transcript
- Avinger's (AVGR) CEO Jeff Soinski on Q3 2020 Results - Earnings Call Transcript
- 11/10/2020
|
What Historical Figures Say About This Stock? Snap Inc. (NYSE:SNAP), Avinger, Inc. (NASDAQ:AVGR) - Stocks Equity
- Snap Inc. (NYSE:SNAP) with the stream of -2.41% also noticed, India Avinger, Inc. (NASDAQ:AVGR) encountered a rapid change of 0.55% in the last hour of Friday’s trading session. Snap Inc. …
- 09/19/2020
|
LightBox Expo Artistically Reinvents The Virtual Show Experience
- The arts and animation show offers some intriguing new twists to the online convention formula.
- 09/10/2020
|
Volatile Movements: Avinger, Inc. (AVGR), Mallinckrodt plc (MNK) - Stocks Equity
- Avinger, Inc. (NASDAQ:AVGR) with the stream of -1.88% also noticed, India Mallinckrodt plc (NYSE:MNK) encountered a rapid change of 7.38% in the last hour of Wednesday’s trading session. Avinger, Inc. …
- 08/27/2020
|
Every American home is getting a flood risk score – and many are at higher risk than previously known
- Starting this week, every homeowner and potential homebuyer in America will be able to see a new analysis of their property's flood risk. It could have a huge impact on the national housing market.
- 08/26/2020
|
Avinger Closes $5.2 Million Underwritten Public Offering of Common Stock | | IT Business Net
- REDWOOD CITY, CA / ACCESSWIRE / August 25, 2020 / Avinger, Inc. (NASAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system f
- 08/25/2020
|
Return On Capital Employed Overview: Avinger
- During Q2, Avinger (NASDAQ: AVGR) brought in sales totaling $1.50 million. However, earnings decreased 34.44%, resulting in a loss of $3.59 million. In Q1, Avinger brought in $2.26 million in sales but lost $5.48 million in earnings.What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Avinger posted an ROCE of -0.48%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on AVGRROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Avinger is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.For Avinger, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q2 Earnings Insight Avinger reported Q2 earnings per share at $-0.18/share, which beat analyst predictions of $-0.2/share.See more from Benzinga * Looking Into Newmont Goldcorp's Return On Capital Employed * ROCE Insights For Overstock.com * Return On Capital Employed Overview: Unity Biotechnology(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/17/2020
|
Avinger Announces Exercise and Closing of Underwriter’s Over-Allotment
- REDWOOD CITY, CA / ACCESSWIRE / August 11, 2020 / Avinger, Inc.
- 08/11/2020
|
Aegis Capital Corp. acted as Sole Bookrunner on a $6,000,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR)
- NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Aegis Capital Corp.
- 08/10/2020
|
Avinger Closes $6 Million Underwritten Public Offering of Common Stock | | IT Business Net
- REDWOOD CITY, CA / ACCESSWIRE / August 6, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system f
- 08/06/2020
|
Avinger : Closes $6 Million Underwritten Public Offering of Common Stock | MarketScreener
|
Avinger Closes $6 Million Underwritten Public Offering of Common Stock
- REDWOOD CITY, CA / ACCESSWIRE / August 6, 2020 / Avinger, Inc.
- 08/06/2020
|
Avinger (AVGR) Upgraded to Buy: Here's What You Should Know
- Avinger (AVGR) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 08/04/2020
|
Avinger : Prices $6 Million Underwritten Public Offering of Common Stock | MarketScreener
|
Avinger Prices $6 Million Underwritten Public Offering of Common Stock | | IT Business Net
- REDWOOD CITY, CA / ACCESSWIRE / August 3, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system f
- 08/04/2020
|
Avinger Prices $6 Million Underwritten Public Offering of Common Stock
- REDWOOD CITY, CA / ACCESSWIRE / August 3, 2020 / Avinger, Inc.
- 08/04/2020
|
Avinger's (AVGR) CEO Jeff Soinski on Q2 2020 Results - Earnings Call Transcript
- Avinger, Inc. (NASDAQ:AVGR) Q2 2020 Earnings Conference Call July 30, 2020 4:30 PM ET Company Participants Matt Kreps – Managing Director-Darrow Associates Investor Relations Jeff Soinski – Chief Executive Officer Mark Weinswig – Chief Financial Officer Conference Call Participants Nathan Weinstein – Aegis Capital Presentation Operator Greetings, and welcome to Avinger’s 2020 Second Quarter Conference call.
- 07/31/2020
|
Avinger Reports Second Quarter 2020 Financial Results
- REDWOOD CITY, CA / ACCESSWIRE / July 30, 2020 / Avinger, Inc.
- 07/30/2020
|
Avinger to Announce Second Quarter 2020 Results on July 30, 2020 | | IT Business Net
- REDWOOD, CA / ACCESSWIRE / July 27, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for dia
- 07/27/2020
|
Avinger : to Announce Second Quarter 2020 Results on July 30, 2020 | MarketScreener
|
Avinger to Announce Second Quarter 2020 Results on July 30, 2020
- REDWOOD, CA / ACCESSWIRE / July 27, 2020 / Avinger, Inc.
- 07/27/2020
|
Avinger Announces Exercise and Closing of Underwriter's Over-Allotment Offering
- REDWOOD CITY, CA / ACCESSWIRE / July 9, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease ("PAD"), today announced that the underwriters of its previously announced underwritten public offering have exercised, in full, their option to purchase an additional 3,000,000 shares of its common stock at a price of $0.27 per share. The shares were offered pursuant to a registration statement on Form S-1 (File No. 333-239177) previously filed with the Securities and Exchange Commission ("SEC"), and a related registration statement on Form S-1 (File No. 333-239398) filed pursuant to rule 462(b) of the Securities Act of 1933, which registration statements were declared effective by the SEC.
- 07/09/2020
|
Flinto raises $7.2 million in pre-series B funding
- Flintobox is the company's flagship product - it is a subscription service of toys and material that help children learn.
- 07/02/2020
|
[Funding alert] Edtech startup Flinto raises $7.2M in Pre-Series B led by Lightbox Ventures
- Edtech startup Flinto will use this funding to support its rapid growth in the early learning space and to expand its newly-launched preschool solution.
- 07/02/2020
|
2 Beaten-Up Penny Stocks That Are Set for a Rebound
- With the outbreak of the coronavirus, volatility has become a seemingly ever-present facet of the stock market. While the current economic landscape has spurred fear among investors, others view market volatility as a unique buying opportunity.Opportunity is the key word – and sometimes the hardest thing for investors to see. To find names that can deliver solid returns and now come with a bargain price tag, investors will often turn to penny stocks, or those trading for less than $5 per share.Sure, there could be a very good reason these tickers are so affordable, but should there be even minor share price appreciation, massive percentage gains could materialize, along with hefty profits for investors.So, how are investors supposed to determine which names have what it takes to make a comeback? Follow the pros.Using TipRanks’ database, we were able to pinpoint two promising penny stocks, according to the analyst community. Although each has fallen below $3, the Buy-rated tickers appear poised to take off on an upward trajectory, boasting colossal upside potential.Xeris Pharmaceuticals (XERS)Based on its innovative technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, Xeris Pharmaceuticals provides solutions that simplify the process of administering important therapies. Even though its public offering prompted a serious sell-off on June 25, with the one-day loss coming in at 49%, the new $2.59 share price could allow investors to get in on the action before XERS blasts off.Representing Piper Sandler, analyst David Amsellem believes that the Street is underestimating XERS. Pointing to the results from its Phase 2 proof-of-concept study evaluating XP-3924, its liquid-stable, ready-to-use (RTU) coformulation of pramlintide and insulin in adult patients with type 1 diabetes, the analyst is optimistic about the candidate’s prospects going forward.The trial was designed as a randomized, open-label, 3-arm, cross-over study enrolling 18 adult participants, who were randomized to receive subcutaneous injections (SC) of XP-3924, regular insulin or co-administration of Symlin and insulin. It should be noted that Symlin is AstraZeneca’s product that needs to be injected separately from insulin, while Xeris' asset is given as a single injection.Importantly, post-prandial treatment with XP-3924 resulted in a 62% decrease in hyperglycemia compared to treatment with insulin alone. Adding to the good news, Amsellem highlights that glycemic control associated with XP-3924 was in line with that of the co-administration of pramlintide-insulin, and that glucose variability, or the variation of all plasma glucose levels across the six-hour monitoring period, was lower in patients treated with XP-3924 versus insulin alone and the co-administration of insulin with Symlin.“We do not believe that meaningful value is being ascribed to this opportunity (or other pipeline shots-on-goal for that matter), given our bullish view of the opportunity for Gvoke in severe hypoglycemia rescue (i.e., peak U.S. sales of $250 million-plus are realistic),” Amsellem commented.Looking ahead, Amsellem expects XERS to seek out a development partner, with management indicating “it could play a role in pramlintide-insulin commercialization with a partner given that the company already calls on endocrinologists in its support of Gvoke.” The analyst added, “As an aside, management also suggested that it would seek a partner for its injectable diazepam product for seizure clusters, though this is a relatively inexpensive development program focused on a concentrated prescriber audience, so in that vein, keeping full rights here would not be out of the question.”To this end, Amsellem rates XERS an Overweight (i.e. Buy) along with an $11 price target. This target implies shares could climb 326% higher in the next year. (To watch Amsellem’s track record, click here) Do other analysts agree with Amsellem? They do. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $12.50, the average price target puts the potential twelve-month gain at 373%. (See XERS stock analysis on TipRanks)Avinger (AVGR)Avinger is a medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD).AVGR also tumbled recently on account of a $5.4 million public offering. Currently going for only $0.29 apiece, one member of the Street believes that now is the right time to snap up shares.Aegis Capital’s Nathan Weinstein notes that its recent capital raise via equity financing, its $2.3 million PPP loan and cash and equivalents of $9.9 million as of March 31, as well as its efforts to trim operating costs “have helped strengthen the company's balance sheet and financial runway.”Weinstein doesn’t dispute the fact that the current operating environment presents significant challenges including a pull-back in sales thanks to the pandemic, and a move to utilize virtual sales and marketing tools. That being said, AVGR’s clinical representatives continue to operate on customer sites when it’s possible.Expounding on this, the analyst stated, “A lack of clarity regarding a ‘return to normalcy’ pervades markets broadly, and PAD procedures are no exception. With that said, our current outlook calls for a gradual return to normalcy in patient volumes and customer ordering activity as we move forward through the calendar.”On top of this, there are several key catalysts on the horizon, in Weinstein’s opinion. These include the 510(k) submission for the Ocelaris image-guided CTO crossing catheter this quarter, the 510(k) submission for the L300 imaging console in 2H:20 and the completion of the INSIGHT IDE clinical study, which was designed to assess the safety and efficacy of Pantheris as a treatment for in-stent restenosis. Should the results be positive, they could support label expansion for Pantheris.“While we think each of these on their own are important, when we step-back and view the overall portfolio being completely refreshed, we believe the salesforce will be well-positioned to capitalize on the large PAD-treatment opportunity, especially when case volumes return,” Weinstein commented.In line with Weinstein’s optimistic take, he reiterates a Buy recommendation on AVGR. His $1.40 price target implies a twelve-month gain of 368% from current levels. (To watch Weinstein’s track record, click here) AVGR has stayed relatively under-the-radar so far, with its Moderate Buy consensus rating breaking down into 1 Buy and 1 Hold. Additionally, the $1.40 average price target matches Weinstein’s. (See Avinger stock-price forecast on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/01/2020
|
Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ: AVGR) | | IT Business Net
- NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR) About Avinger Inc. Avinger is a commercial-st
- 06/29/2020
|
Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ: AVGR)
- NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR) About Avinger Inc. Avinger is a commercial-stage ...
- 06/29/2020
|
Avinger Closes $5.4 Million Underwritten Public Offering of Common Stock | | IT Business Net
- REDWOOD CITY, CA / ACCESSWIRE / June 26, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system fo
- 06/26/2020
|
Avinger Closes $5.4 Million Underwritten Public Offering of Common Stock
- REDWOOD CITY, CA / ACCESSWIRE / June 26, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 20,000,000 shares of its common stock at a price of $0.27 per share, for total gross proceeds of approximately $5.4 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 15% additional shares of common stock to cover over-allotments, if any. The shares were offered pursuant to a registration statement on Form S-1 (File No. 333-239177) previously filed with the Securities and Exchange Commission (SEC), and a related registration statement on Form S-1 (File No. 333-239398) filed pursuant to rule 462(b) of the Securities Act of 1933, which registration statements were declared effective by the SEC.
- 06/26/2020
|
Avinger Prices $5.4 Million Underwritten Public Offering of Common Stock | | IT Business Net
- REDWOOD CITY, CA / ACCESSWIRE / June 23, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system fo
- 06/24/2020
|
Avinger Prices $5.4 Million Underwritten Public Offering of Common Stock
- REDWOOD CITY, CA / ACCESSWIRE / June 23, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be $5.4 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The proposed offering equates to 20 million shares of the Company's common stock at a price of $0.27 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company's Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures.
- 06/24/2020
|
Los índices de Estados Unidos cierran a la baja; el Dow Jones Industrial Average cae un 2,72%
- Los índices de Estados Unidos cierran a la baja; el Dow Jones Industrial Average cae un 2,72%
- 06/24/2020
|
TIFF cuts 31 full-time positions, forecasts revenue drop of 50 per cent
- The move, which reduces TIFF’s full-time staff by 17 per cent, comes at a time when the institution is facing pressures both external and internal
- 06/23/2020
|
Rising P/E: An Overlooked Trick to Pick 5 Winning Stocks
- Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- 06/10/2020
|
Hedge Funds Are Warming Up To Avinger Inc (AVGR)
- In this article we will take a look at whether hedge funds think Avinger Inc (NASDAQ:AVGR) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]
- 05/29/2020
|
Avinger (AVGR) Upgraded to Strong Buy: Here's Why
- Avinger (AVGR) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/28/2020
|
Edited Transcript of AVGR earnings conference call or presentation 13-May-20 8:30pm GMT
- Q1 2020 Avinger Inc Earnings Call
- 05/26/2020
|
FX Greenlights ‘AHS’ Spinoff ‘American Horror Stories’, Renews ‘Better Things’ & ‘The Weekly’ As Part Of 2020-21 Programming Slate
- FX has given formal green light to American Horror Stories, a spinoff of Ryan Murphy’s venerable anthology series American Horror Story. It is part of FX’s original programming slate through …
- 05/26/2020
|
Avinger Announces 510(k) Filing of Ocelaris Next Generation Image-guided CTO Crossing System
- REDWOOD CITY, CA / ACCESSWIRE / May 20, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the Company has submitted a 510(k) application to the U.S. Food & Drug Administration (FDA) for pre-marketing clearance of Ocelaris, a next generation chronic total occlusion (CTO) crossing system utilizing Avinger's proprietary image-guided technology platform. Ocelaris is a product line extension of Avinger's Ocelot family of image-guided CTO crossing catheters. Its design elements include an upgrade of the image capture rate to provide high definition, real-time intravascular imaging similar to the company's Pantheris image-guided atherectomy system and a user-controlled deflectable tip designed to assist in steerability within the lumen.
- 05/20/2020
|
LightBox and First Street Foundation Partner to Provide A New Model for Flood Data Covering 145 Million Properties in United States
- LightBox, a leading provider of CRE data and workflow solutions, and First Street Foundation, a nonprofit 501(c)(3) research and technology group, announced a partnership that will provide new data and analytic capabilities to support the valuation, underwriting, and assessment of commercial and residential property risk due to natural flood-related disasters.
IRVINE, Calif. and BROOKLYN, N.Y. (PRWEB) May 19, 2020
LightBox, a leading provider of CRE data and workflow solutions, and First Street Foundation, a nonprofit 501(c)(3) research and technology group, announced a partnership today that will provide new data and analytic capabilities to support the valuation, underwriting, and assessment of commercial and residential property risk due to natural flood-related disasters.
The partnership offers the first predictive, probabilistic model to estimate the impact of climate change on flooding down to the individual property level. The model can be used by property owners, investors, appraisers, lenders, and insurance companies to better understand and mitigate risk, including changes in property valuation due to flood-related events.
The announcement was made as the United States prepares for the June 1 start of hurricane season. Since 1980, over $1 trillion in damages can be attributed to flood-related events in the United States with nearly $41 billion in losses from events in 2019, according to NOAA.
As part of the partnership, LightBox is providing property and location data for more than 145 million U.S. properties via SmartParcels®, the most complete parcel database in North America. First Street will provide its climate-adjusted, predictive flood data and statistics based on future potential climate states as projected by the Intergovernmental Panel on Climate...
- 05/19/2020
|
Avinger Reports First Quarter 2020 Financial Results
- 23% Year-Over-Year Revenue Growth Total Pantheris Revenue Increases 75% REDWOOD CITY, CA / ACCESSWIRE / May 13, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the ...
- 05/13/2020
|
Avinger to Announce First Quarter 2020 Results on May 13, 2020
- REDWOOD CITY, CA / ACCESSWIRE / May 7, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis ...
- 05/07/2020
|
Avinger Announces Exercise and Closing of Underwriter's Over-Allotment Offering
- REDWOOD CITY, CA / ACCESSWIRE / May 6, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,890,000 shares of its common stock at a price of $0.25 per share. The shares were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus relating to the offering was filed with the SEC and is available on the SEC's website at www.sec.gov.
- 05/06/2020
|
#StartupsVsCovid19: SaaS Models Need To Evolve As SMBs Go Online, Says Sequoia’s GV Ravishankar
- The coronavirus pandemic has unleashed a ton of disruption for businesses at large, but small-medium businesses (SMBs) in particular have been impacted heavily.
- 05/04/2020
|
Avinger Closes $3.15 Million Equity Offering
- REDWOOD CITY, CA / ACCESSWIRE / April 30, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 12,600,000 shares of its common stock at a price of $0.25 per share, for total gross proceeds of approximately $3.15 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 15% additional shares of common stock to cover over-allotments, if any. The shares were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission (SEC).
- 04/30/2020
|
These Bay Area public companies nabbed PPP loans
- The second phase of the SBA's Paycheck Protection Program opened up to applications on April 27.
- 04/29/2020
|
Stocks That Hit 52-Week Lows On Tuesday
- On Tuesday, the following stocks hit new 52-week lows.
Significant Points:
Southwest Airlines (NYSE: LUV) was the biggest company on a market cap basis to set a new 52-...
- 04/28/2020
|
Avinger Prices $3.15 Million Underwritten Public Offering of Common Stock
- REDWOOD CITY, CA / ACCESSWIRE / April 27, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $3.15 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The proposed offering equates to 12.6 million shares of the Company's common stock at a price of $0.25 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company's Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures.
- 04/28/2020
|
Bet on Rising P/E Investing With These Top 5 Stocks
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
- 04/24/2020
|
Bet on Rising P/E Investing With These Top 5 Stocks
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
- 04/24/2020
|
Omnichannel Going To Be New Reality As People Switch To Ecommerce
- Experts believe that the gap is shrinking and thanks to the coronavirus outbreak, even offline players are coming online now.
- 04/17/2020
|
Financial Contrast: Avinger (NASDAQ:AVGR) vs. Inspire Medical Systems (NASDAQ:INSP)
- Avinger (NASDAQ:AVGR) and Inspire Medical Systems (NYSE:INSP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations. Profitability This table compares Avinger and Inspire Medical Systems’ net margins, return on equity and […]
- 04/17/2020
|
Avinger Reports Preliminary First Quarter 2020 Revenue Results
- REDWOOD CITY, CA / ACCESSWIRE / April 15, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported preliminary results for the first quarter ended March 31, 2020. Revenue in the first quarter of 2020 is expected to be approximately $2.25 million, an increase of 22% over the first quarter of 2019, representing the company's third consecutive quarter with greater than 20% year-over-year revenue growth. Avinger launched 11 new Lumivascular sites during the first quarter in high volume areas, such as Arizona, Michigan, and Louisiana, which also contributed to revenue growth for the quarter.
- 04/15/2020
|
Coronavirus impact: Early funding of start-ups may hit a stumbling block
- This comes as seed investments in India during the January-March quarter, which was hit by the lowest level in five quarters
- 04/05/2020
|
Funding Galore: Indian Startup Funding Of The Week
- 12 startups raised around $116.85 Mn funding and one startup acquisition took place in the Indian startup ecosystem this week.
- 04/04/2020
|
AVGR-Is The Stock Worthy? Avinger, Inc. (NASDAQ:AVGR) Revenue has been moving by N/A on average over the past 5 years - Stocks Equity
- On Wednesday, shares of Avinger, Inc. (NASDAQ:AVGR) reached at $0.32 price level during last trade its distance from 20 days simple moving average was -40.17%, [...]
- 03/18/2020
|
With TIFF closing Lightbox over coronavirus, the future looks dark for Canadian filmgoers, and filmmakers
- The entire film industry is surely asking themselves which organization might go dark next
- 03/14/2020
|
Edited Transcript of AVGR earnings conference call or presentation 5-Mar-20 9:30pm GMT
- Q4 2019 Avinger Inc Earnings Call
- 03/13/2020
|
Avinger Reports Fourth Quarter 2019 Financial Results
- 26% Year-Over-Year Fourth Quarter Revenue Growth Total Pantheris Revenue Increases 69% REDWOOD CITY, CA / ACCESSWIRE / March 5, 2020 / Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company ...
- 03/05/2020
|
Avinger, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 5, 2020 / Avinger, Inc. (AVGR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 4:30 PM Eastern Time. ...
- 03/05/2020
|
Avinger to Announce Fourth Quarter 2019 Financial Results on March 5, 2020
- REDWOOD CITY, CA / ACCESSWIRE / February 27, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...
- 02/27/2020
|
Avinger Announces Publication of SCAN Clinical Study in Peer-Reviewed Journal
- REDWOOD CITY, CA / ACCESSWIRE / February 25, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the results of its SCAN clinical study have been published in the peer-reviewed journal BMC Medical Imaging. SCAN is a prospective, non-inferiority, post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. Study results showed that OCT imaging with Avinger's Pantheris system demonstrated statistical superiority or equivalence to IVUS on all parameters evaluated.
- 02/25/2020
|
Reviewing Axonics Modulation Technologies (NASDAQ:AXNX) and Avinger (NASDAQ:AVGR)
- Axonics Modulation Technologies (NASDAQ:AXNX) and Avinger (NASDAQ:AVGR) are both small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Profitability This table compares Axonics Modulation Technologies and Avinger’s net margins, return on equity and return […]
- 02/17/2020
|
Avinger's Pantheris Featured in Live Case Transmission at LINC 2020
- REDWOOD, CA / ACCESSWIRE / February 4, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), announced today that its Pantheris atherectomy system was featured in a live case transmission at the Leipzig Interventional Course (LINC) 2020, a leading global forum for new methods in the field of vascular medicine held from January 28 through January 31 in Leipzig, Germany. Dr. Arne Schwindt and Dr. Angeliki Argyriou, vascular surgeons from St. Franziskus Hospital in Münster, Germany, performed the live endovascular procedure using Pantheris during a session entitled, "OCT-guided atherectomy of popliteal stent ISR followed by DCB." The patient for the live case presented with claudication and rest pain in the right leg, stemming from blockages within stents placed in a popliteal vein graft.
- 02/04/2020
|
Avinger Closes $4.5 Million Equity Offering
- REDWOOD CITY, CA / ACCESSWIRE / January 31, 2020 / Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 6,428,572 shares of its common stock at a price of $0.70 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The shares were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus relating to the offering was filed with the SEC and is available on the SEC's website at www.sec.gov.
- 01/31/2020
|
Avinger Announces the Passing of Director Donald A. Lucas
- REDWOOD CITY, CA / ACCESSWIRE / January 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...
- 01/30/2020
|
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
- REDWOOD CITY, CA / ACCESSWIRE / January 28, 2020 / Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 6,428,572 shares of the Company's common stock at a price of $0.70 per share. The Company intends to use the net proceeds from this offering to fund working capital, payment of interest on debt and general corporate purposes, which may include research and development of the Company's Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures.
- 01/29/2020
|
Avinger Enrolls First Patient in IMAGE-BTK Clinical Study Evaluating Safety and Efficacy Endpoints for Pantheris SV
- Post-Market Study Intended to Support Commercial Expansion of Small Vessel Image-Guided Atherectomy Device REDWOOD CITY, CA / ACCESSWIRE / January 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage ...
- 01/23/2020
|
Whiteboard Capital mixes incubator, micro-VC approach
- As the name suggests, Whiteboard Capital bet on founders even before their business plan is finalised and to help them refine their products, even if it means changing the model.
- 12/08/2019
|
Ikea, Hovis, Argos and TK Maxx recall products over safety fears
- Trading Standards has released a list of products which are mislabelled or do not comply with safety measures
- 03/18/2019
|
Flintobox Raises $7 Mn In Series A Funding Round Led By Lightbox
- With this funding, GSF Accelerator takes an exit from Flintobox, which now plans to expand its business in the unorganised pre-school segment.
- 12/06/2017
|
This Top Analyst Says Avinger Inc (AVGR) Must Find a Buyer ASAP
- Avinger Inc (NASDAQ:AVGR) released second-quarter earnings last evening that have left top analyst Jason Mills at Canaccord firmly on the sidelines. While
- 08/09/2017
|
Sell-Side Analysts Take Action on Two Rising Stocks: Avinger Inc (AVGR), Moneygram International Inc (MGI)
- Though Avinger Inc (NASDAQ:AVGR) and Moneygram International Inc (NASDAQ:MGI) investors are out cheering and sending the stocks on a clear rise, analysts
- 01/27/2017
|
Print Article
- Visit the post for more.
- 08/14/2014
|
